AGIO

Agios Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-12

Figures on this page computed 2026-11-08 12:48 UTC

Last close

28.27USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-02-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-12
The filing itself
-41.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
-764.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
-698.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
The filing itself
0.03Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-07-30
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.12 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.18x

13.05x

1.24x

0.52x

0.65x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-12

Sales1.18x
Its own average over 10 years, 45.7M.
Profit13.05x
Its own average over 10 years, -31.6M.
Free cash flow1.24x
Its own average over 10 years, -305.3M.
Debt0.52x
Its own average over 6 years, 77.6M.
Price0.65x
Its own average over 11 years, 43. Market data, 2026-11-05

Profit is furthest from its own average, at 13.05 times.

Sales is 1.18 times its own 10-year average; Profit is 13.05 times its own 10-year average; Free cash flow is 1.24 times its own 10-year average; Debt is 0.52 times its own 6-year average; Price is 0.65 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-12

Sales against its own 10-year average1.18
Source
filed
Statement
income
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
The filing itself
Profit against its own 10-year average13.05
Source
filed
Statement
income
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.24
Source
filed
Statement
income
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
The filing itself
Debt against its own 6-year average0.52
Source
filed
Statement
income
Fiscal year
2025
Accession
0001439222-26-000025
Reported in
USD
The filing itself
Price against its own 11-year average0.65Market data, 2026-11-05
Source
market
Taken on
2026-11-05
Reported in
USD